The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing ...

Dan, diagnosed with stage 4 pancreatic cancer, shares his journey to remission and insights on clinical trials and patient ...

How does personalised medicine work across different cancer types? Oncologist Dr Valerie Yang from OncoCare Cancer Centre ...

A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.

Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct ...

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., /PRNe ...

VANCOUVER, BC / ACCESS Newswire / December 10, 2025 / Lir Life Sciences Corp. ("Lir" or the "Company") is pleased to announce ...

Onconic Therapeutics announced on December 11 that it has been officially invited for the second consecutive year to participate in the '2026 JP ...

As patients turn to smartphones for answers, Kerala’s doctors and health systems must evolve to guide, filter, and humanise ...

Devastating news became a regular occurrence as the cancer progressed - repeat bowel obstructions, emergency stoma surgery, ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutationPhase 2 results ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation ...